Myocardial Infarction Treatment Market Projected to Reach $15.7 Billion by 2035

Myocardial Infarction Treatment market was valued at $8.6 billion in 2025 and is projected to reach $15.7 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2026-2035). The global myocardial infarction treatment market is witnessing significant growth, primarily driven by the increasing prevalence of cardiovascular conditions and the rising number of myocardial infarction cases. Factors such as an aging population, sedentary lifestyles, obesity, diabetes, and smoking habits are contributing to a higher incidence of cardiac events, thereby increasing the demand for effective treatment options, including pharmacological therapies, interventional procedures, and surgical approaches. In the US, heart disease remains the leading cause of mortality, with approximately 919,032 cases recorded in 2023, accounting for nearly 1 in every 3 cases. Additionally, cardiovascular conditions impact individuals at a rapid rate, with one case occurring every 34 seconds. The burden of myocardial infarction is also substantial, as one heart attack occurs every 40 seconds, translating to nearly 805,000 cases annually, of which 605,000 are first-time occurrences and 200,000 are recurrent events. Furthermore, nearly 1 in 5 myocardial infarctions are silent, where individuals remain unaware despite underlying cardiac damage.

Browse the full report description of “Myocardial Infarction Treatment Market Size, Share & Trends Analysis Report by Infarction Type (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction), by Treatment Type (Pharmacological Treatment (Antiplatelet Agents, Anticoagulants, Thrombolytics, Beta Blockers, ACE Inhibitors and Others), Interventional Treatment and Surgical Treatment (CABG)), and by End User (Hospitals, Specialty Cardiac Clinics and Ambulatory Surgical Centers), Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/myocardial-infarction-treatment-market

Simultaneously, the increasing number of US Food and Drug Administration (FDA) Fast Track Designations is playing a crucial role in accelerating the development and approval of innovative therapies targeting myocardial infarction. This regulatory pathway enables faster clinical advancement and earlier availability of novel drugs, thereby strengthening the treatment landscape. Pharmaceutical companies are leveraging these opportunities to enhance their cardiovascular pipelines and introduce advanced therapeutics, including next-generation antiplatelet and anticoagulant agents. For instance, in March 2025, FDA granted Fast Track Designation to SGC001, a monoclonal antibody developed by Sungen Biomedical for the emergency treatment of Acute Myocardial Infarction. The therapy is designed to reduce cardiomyocyte damage by inhibiting apoptosis, lowering oxidative stress, and improving blood perfusion in ischemic areas. Currently in Phase 1 clinical trials, SGC001 represents the first antibody-based approach in this indication and may introduce a new treatment pathway if approved. Hence, the combined impact of rising disease incidence, high case volumes, and supportive regulatory initiatives is expected to drive sustained growth in the myocardial infarction treatment market over the forecast period.

Competitive Landscape and Recent Developments

The global myocardial infarction treatment market is highly competitive, with several leading pharmaceutical companies playing a key role in driving innovation and market growth. Prominent players include AstraZeneca PLC, Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others. These companies are actively engaged in developing advanced therapies, expanding their product portfolios, and strengthening their global presence to address the growing burden of cardiovascular diseases.

• In March 2026, Abbott launched the XIENCE Skypoint drug-eluting stent in India, designed for complex Percutaneous Coronary Intervention procedures involving large vessels and long lesions. The stent offers an expanded size range up to 5.25 mm and enables treatment of extended blockages with a single-stent approach, improving procedural efficiency. This development strengthens advanced interventional options for managing Myocardial Infarction and other coronary artery conditions.

• In November 2025, CeleCor Therapeutics reported positive Phase 3 results for zalunfiban, an investigational antiplatelet therapy for ST-Elevation Myocardial Infarction, with plans to file for approval with the U.S. Food and Drug Administration in early 2026. The subcutaneous drug, designed for administration at first medical contact, demonstrated improved blood flow and a 21% reduction in risk of major cardiac complications compared to placebo, without a significant increase in major bleeding.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Infarction Type
• Treatment Type
• End-User
• Competitive Landscape – AstraZeneca PLC, Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Myocardial Infarction Treatment Market Report Segment

By Infarction Type

• ST-Elevation Myocardial Infarction (STEMI)
• Non-ST-Elevation Myocardial Infarction (NSTEMI)

By Treatment Type

• Pharmacological Treatment
  • Antiplatelet Agents
  • Anticoagulants
  • Thrombolytics
  • Beta Blockers
  • ACE Inhibitors
  • Others
• Interventional (PCI-based) Treatment
• Surgical Treatment (CABG)

By End-User

• Hospitals
• Specialty Cardiac Clinics
• Ambulatory Surgical Centers

Global Myocardial Infarction Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/myocardial-infarction-treatment-market